03613.HK
TONGRENTANGCM
HKSE · Healthcare · Medical - Pharmaceuticals · HK
HKD 5.65
+2.08%Year over year
Reported trailing growth
- Revenue
- -3.2%
- EBITDA
- +6.6%
- EBIT
- -8.5%
- EPS
- -10.9%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -4.4%
- EBITDA
- -14.1%
- EBIT
- -16.5%
- Net income
- -15.0%
- EPS
- -15.2%
- Free cash flow
- +17.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026